MedicaidPrior AuthLow impact
Fyarro (sirolimus protein-bound particles for injectable suspension) (Revised)
Humana·IN · Oncology, Pharmacy·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Indiana Medicaid has established a new prior authorization policy for Fyarro (sirolimus protein-bound particles), a cancer treatment for perivascular epithelioid cell tumors. Prior authorization will be required starting January 1, 2026, with specific criteria including locally advanced unresectable or metastatic diagnosis and monotherapy administration.
Action Required
By January 1, 2026: Billing team must update prior authorization requirements for Fyarro (sirolimus protein-bound particles) for Indiana Medicaid patients. Ensure providers obtain prior auth by confirming patient has locally advanced unresectable or metastatic perivascular epithelioid cell tumor and drug will be used as monotherapy. Claims will be denied without proper prior authorization.